{
    "nct_id": "NCT02927769",
    "official_title": "Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)",
    "inclusion_criteria": "* Classic Hodgkin Lymphoma (cHL), relapsed or refractory\n* Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.\n* One prior anti-cancer therapy that did not work\nHealthy volunteers allowed\nMust have minimum age of 5 Years\nMust have maximum age of 30 Years",
    "exclusion_criteria": "* Active, known, or suspected autoimmune disease or infection\n* Active cerebral/meningeal disease related to the underlying malignancy\n* More than one line of anti-cancer therapy or no treatment at all\n* Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant\n* Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}